On July 18, Gelunhui reported that Longeveron (LGVN.US), a concept stock for Alzheimer's therapy, rose 1.79% before the market, reaching $3.97. According to the news, Lomecel-b has been granted a fast-track designation by the US FDA for the treatment of mild Alzheimer's disease. It is reported that investigational therapies designated as fast-track may be eligible for priority review if they meet certain criteria at the time of submission of the application to the FDA, and may undergo rolling FDA review.
美股异动丨Longeveron盘前涨近2% 获得FDA授予快速通道设计
US stocks fluctuate | Longeveron rose nearly 2% before the market and received FDA approval for fast track design.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.